GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday.

GSK blood cancer drug nearly halves risk of death in late-stage trial

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?

Deutsche Bank

GSK's development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma's top R&D executives. Work needs to be done to rebuild the innovation proposition in the eyes of many investors, but Deutsche Bank sees clear emergent strands of underappreciated potential.

GSK development pipeline underrated suggests Deutsche Bank

AstraZeneca

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.

AstraZeneca started at buy at Goldman, which rates GSK a neutral

On May 1, London-based GSK published financial results for the first three months of 2024, which pleasantly surprised me. Sales of Jemperli for the first three months of 2024 amounted to about $101 million, up 46.6% from the previous quarter. The company has a rich pipeline of investigational vaccines and drugs, many of which have the potential to become "gold standards" in the fight against various viruses and disorders.

GSK plc: Long-Term Cash Cow

British pharmaceuticals big cap GSK PLC (LSE:GSK, NYSE:GSK) has won a high-stake personal injury case in the state of Illinois, US, over its heartburn medication Zantac. A jury determined that Zantac was not responsible for the plaintiff's colon cancer, with the judge rejecting a request for $640 million in damages.

GSK found not guilty in Zantac trial

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why GSK (GSK) is a Top Momentum Stock for the Long-Term

GSK's GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.

GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinical trials. Financially, GSK shows solid earnings growth but has a current ratio below 1, indicating possible liquidity issues.

GSK Breathes New Life Into Asthma Treatment With Depemokimab

GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the investment banking arm of Barclays. Zantac was pulled from the market in 2019 after the US Food and Drug Administration (FDA) found it contained N-nitrosodimethylamine (NDMA), a probable carcinogen.

GSK: Zantac settlement could reach $2bn, says investment bank

GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.

GSK says late-stage trials of potential blockbuster asthma drug met their goals

GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.

GSK's asthma drug shows promise in reducing severe attacks

GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug.

GSK faces whistleblower lawsuit over Zantac cancer risk

Haleon PLC

GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant back in 2022. On Friday, the Brentford-based firm revealed it raised £1.24 billion after it sold the final part of its stake in Haleon, offloading more than 385 million shares at 324p each.

GSK confirms exit of Haleon stake for £3.9 billion

GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.

GSK raises $1.5 bln from offloading Haleon stake at a discount

British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.

GSK intends to sell its remaining stake in Haleon

BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc (LSE/NYSE: GSK) to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

This covered call equates to a 6.26% return, or 22.17% on an annualized basis.

GSK Stock Today: Buying An August Covered Call Boosts Your Return By This Much

GSK plc (NYSE:GSK ) Q1 2024 Earnings Conference Call May 1, 2024 3:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Julie Brown - Chief Financial Officer Tony Wood - Chief Scientific Officer Conference Call Participants Mark Purcell - Morgan Stanley Kerry Holford - Joh. Berenberg, Gossler & Co. Graham Parry - Bank of America Merrill Lynch Jo Walton - UBS Stephen Scala - TD Cowen Simon Baker - Redburn Atlantic James Gordon - JPMorgan Emily Field - Barclays Bank PLC Richard Parkes - BNP Paribas Peter Verdult - Citigroup Inc. Peter Welford - Jefferies LLC Timothy Anderson - Wolfe Research, LLC Nick Stone Hello everyone.

GSK plc (GSK) Q1 2024 Earnings Call Transcript

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why GSK (GSK) is a Top Growth Stock for the Long-Term

Apple

Advanced Micro Devices

Alphabet

Mitsubishi Electric Corp

NVIDIA

Yesterday, the biggest company in the world in terms of market cap reported its latest earnings. But Apple Inc. is far from the only blue chip stock around.

5 best blue chip stocks to invest in for sustainable gains in May – excluding Apple Inc. (AAPL)

U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

Affirm

Dominion Energy

Innovative Industrial Properties

Kaiser Aluminum

Organon & Co

Sunoco

Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot of enterprises so I decided to narrow down the list.

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.90 per share a year ago.

News for GlaxoSmithKline Stock (GSK)